Addressing Skin Adverse Events during Mirdametinib Treatment in Patients with Neurofibromatosis Type 1-Associated Plexiform Neurofibromas: Guidance from Experts on the Management of MEK Inhibitor-Associated Skin AEs
Neuropediatrics | April 27, 2026 | Volume: 57 | Issue: No issue available | Pages: No page available
10.1055/s-0046-1822860